Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.69% on an annualized basis producing an average annual return of 10.89%. Currently, Gilead Sciences has a market c
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Cracking The Code: Understanding Analyst Reviews For Merck & Co
Merck & Co (NYSE:MRK) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The following table summarizes their recent ratings, shedding li
GeoVax Stock Rockets 50% on BARDA Award for COVID-19 Vaccine
Stifel Starts Celldex at Buy, Sees Lead Drug as Potential Blockbuster
Day One in Licensing Pact With MabCare for Cancer Therapy
This Is What Whales Are Betting On Bristol-Myers Squibb
Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb.Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 8 trades.If we consider th
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and industry followers. In this article, we will carry o
Today's Morning Movers and Top Ratings: CHGG, KR, GME, STM and More
Gamestop shares declined by 3.05%, extending losses from the prior session, in the wake of CEO Ryan Cohen's announcement regarding the company's strategy to maintain a leaner network of retail stores.
Merck & Co Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 19.92% Cantor Fitzgerald $155 → $155 Reiterates Overweight → Overweight 06/04/2024 19.92% Canto
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
Monday, the FDA approved Merck & Co Inc's (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.It
Merck Gets FDA Approval for Capvaxive-21 Pneumonia Vaccine
Merck's Keytruda Gains Approval for Additional Endometrial Carcinoma Indication
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Pfizer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/17/2024 67.1% Cantor Fitzgerald $45 → $45 Reiterates Overweight → Overweight 05/02/2024 7.69% Morgan St
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
BioNTech SE's (NASDAQ:BNTX) partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.The MediLink-sponsored trial evaluates the early-stage
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020.Magrolimab is a monoclonal antibody targeting CD47 for treating various types
ALS Therapy Market Seen Increasing to Nearly $1.3B by 2029
U.S. Drug Shortages Worsen to Reach a Decade High: Report
Pfizer Stock Traded in the Red for Seven Straight Days